- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Venturi mask.
Displaying page 1 of 1.
| EudraCT Number: 2020-005020-11 | Sponsor Protocol Number: 5000 | Start Date*: 2021-05-04 |
| Sponsor Name:Políclinica Nuestra Señora del Rosario | ||
| Full Title: Randomized multicenter single-blind controlled trial on ozonated blood in COVID-19 severe pneumonia | ||
| Medical condition: Covid-19 pneumonia | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-001390-76 | Sponsor Protocol Number: ESCAPE | Start Date*: 2020-04-27 | |||||||||||
| Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI" | |||||||||||||
| Full Title: A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patie... | |||||||||||||
| Medical condition: Covid-19 coronavirus infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-001671-36 | Sponsor Protocol Number: EC11-103 | Start Date*: 2012-08-27 |
| Sponsor Name:Fundación para la Investigación Biomédica | ||
| Full Title: A phase IV randomized, controlled clinical trial to compare the high flow oxygen therapy (group of intervention) opposite to the conventional oxygen therapy (group control) in patients with severe ... | ||
| Medical condition: Severe acute respiratory failure | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-001745-40 | Sponsor Protocol Number: COVID-SARI-001 | Start Date*: 2020-04-23 | |||||||||||
| Sponsor Name:ASST FATEBENEFRATELLI SACCO | |||||||||||||
| Full Title: PILOT STUDY ON THE USE OF SARILUMAB IN PATIENTS WITH COVID-19 INFECTION | |||||||||||||
| Medical condition: Patients with COVID-19 infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-002567-57 | Sponsor Protocol Number: 1.0 | Start Date*: 2020-11-23 | |||||||||||
| Sponsor Name:University of Oxford / Clinical Trials and Research Governance | |||||||||||||
| Full Title: To determine whether administration of almitrine bismesylate can ameliorate hypoxaemia in Covid-19 and augment effectiveness of supplementary oxygen therapy and respiratory support | |||||||||||||
| Medical condition: Covid-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-001819-12 | Sponsor Protocol Number: CIS-COV | Start Date*: 2022-10-13 | |||||||||||
| Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI" | |||||||||||||
| Full Title: Cysteamine in association with standard therapy for the treatment of hospitalized patients with COVID-19 pneumonia: phase 2 study on safety of a new antiviral and direct therapy on the host | |||||||||||||
| Medical condition: Covid-19 infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-000516-37 | Sponsor Protocol Number: TS-020DESE | Start Date*: 2021-03-04 | |||||||||||
| Sponsor Name:TurnSole Biologics Llc | |||||||||||||
| Full Title: A Phase I/II open-label study for Azacitidine, initiated with a lead-in dose escalation pharmacokinetic Phase I/b part in the 20–50 mg/m2 range to evaluate safety in Hospitalized COVID-19 Patients ... | |||||||||||||
| Medical condition: COVID-19 patients with confirmed sever viral infection of SARS-COV-2 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.